Phase 2 Myeloma Clinical Trials
223 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 223 trials
Recruiting
Phase 2
18F-Fluciclovine PET/CT in Multiple Myeloma
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting
Phase 2
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Multiple Myeloma
National Cancer Institute (NCI)78 enrolled74 locationsNCT06179888
Recruiting
Phase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Noffar Bar50 enrolled2 locationsNCT06993675
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
GlaxoSmithKline200 enrolled6 locationsNCT07227311
Recruiting
Phase 2
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Multiple Myeloma
Memorial Sloan Kettering Cancer Center215 enrolled7 locationsNCT06679829
Recruiting
Phase 2
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Multiple Myeloma (MM)Multiple Myeloma, Newly Diagnosed
SCRI Development Innovations, LLC100 enrolled11 locationsNCT06974786
Recruiting
Phase 2
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Refractory Multiple Myeloma
Ontario Clinical Oncology Group (OCOG)40 enrolled5 locationsNCT06421675
Recruiting
Phase 1Phase 2
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Multiple MyelomaPlasmacytoma
Shenzhen Geno-Immune Medical Institute20 enrolled2 locationsNCT06429150
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 2
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Multiple Myeloma
SCRI Development Innovations, LLC100 enrolled17 locationsNCT05972135
Recruiting
Phase 2
CAR T-cell Therapy in Patients With Renal Dysfunction
Multiple MyelomaAcute Lymphoblastic Leukemia, AdultNon-hodgkin Lymphoma,B Cell
Northside Hospital, Inc.20 enrolled1 locationNCT05909059
Recruiting
Phase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center20 enrolled11 locationsNCT06083922
Recruiting
Phase 1Phase 2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Regeneron Pharmaceuticals387 enrolled40 locationsNCT03761108
Recruiting
Phase 2Phase 3
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple Myeloma
AbbVie660 enrolled38 locationsNCT07095452
Recruiting
Phase 2
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Smoldering Plasma Cell Myeloma
Emory University68 enrolled1 locationNCT04776395
Recruiting
Phase 1Phase 2
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals150 enrolled2 locationsNCT07455851
Recruiting
Phase 2
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Multiple MyelomaPlasma Cell NeoplasmMalignant Plasma Cell Neoplasm
M.D. Anderson Cancer Center30 enrolled1 locationNCT05336383
Recruiting
Phase 2
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Multiple Myeloma (MM)
European Myeloma Network B.V.150 enrolled29 locationsNCT07107529
Recruiting
Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC157 enrolled31 locationsNCT07266441